Abeona Therapeutics Inc ABEO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:59 PM EST
2.37quote price arrow up+0.03 (+1.28%)
Volume
1,871,968
52 week range
0.99 - 3.79

...

Loading . . .

KEY STATS

  • Open2.36
  • Day High2.50
  • Day Low2.32
  • Prev Close2.34
  • 52 Week High3.79
  • 52 Week High Date02/09/21
  • 52 Week Low0.99
  • 52 Week Low Date11/03/20
  • Market Cap233.52M
  • Shares Out98.53M
  • 10 Day Average Volume7.49M
  • Dividend-
  • Dividend Yield-
  • Beta1.53
  • 1 Year % Change-28.02

RATIOS/PROFITABILITY

  • EPS (TTM)-1.04
  • P/E (TTM)-2.29
  • Fwd P/E (NTM)-3.87
  • EBITDA (MRQ)-44.617M
  • ROE (MRQ)-80.35%
  • Revenue (MRQ)7.00M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-1,211.96%
  • Debt To Equity (MRQ)1.53%

EVENTS

  • Earnings Date03/17/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Abeona Therapeutics Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB)...
Michael Amoroso
Chief Operating Officer
Edward Carr
Chief Financial Officer
Address
1330 Avenue of the Americas Fl 33
New York, NY
10019-5442
United States